Today's clearest signal is what is not going to happen. The people who study the government's drug approval process expect no full approval of MDMA or psilocybin — the two most-studied psychedelics — in 2026. MDMA is the drug once known as ecstasy, being tested for severe trauma. Psilocybin is the active ingredient in "magic mushrooms," being tested for deep depression. Neither will clear the finish line this year. Congress won't change the law either. Lawmakers are interested — there are hearings and small study measures — but there is no vote coming to remove these drugs from Schedule 1, the government's most locked-down category for substances it considers to have no accepted medical use.
Meanwhile, two things moved. First, the DEA — the federal drug police — is expected to keep its strict stance and go after unregulated sellers and ceremonies. Sadly, two more deaths from unsupervised ceremonies were reported today. Second, on the money side, one small company, MindMed, jumped over 7% on no real news, while the bigger names barely moved. That tells you these stocks are still driven by rumor and mood, not solid ground.
Beneath the surface, a single thread runs through all of it. The science is moving faster than the law, and the law is moving faster than the streets are ready for. That gap is where both the danger and the promise live. When there is no safe, legal path, desperate people find unsafe ones — and some of them die. Every one of those deaths is a real argument, painful but true, for building a regulated system where trained people guide these experiences. And there's another quiet current: big drug companies are starting to circle. After the recent Eli Lilly deal, more partnerships and buyouts are expected within a year. Big money doesn't chase fantasies — it chases things it believes will one day be real and legal. That interest is a signal that the finish line, while not this year, is genuinely coming into view.
For the people actually waiting, this is the hardest part. Picture a veteran who tried everything for trauma and heard that MDMA might finally help — and now learns it won't be available through a doctor this year. That's a real ache. But here is the honest hope: the path being built now is being built to last. A treatment that arrives slowly but safely, covered and supervised, is worth more than one that arrives fast and falls apart or hurts people. The most positive thing that can happen this year isn't a headline. It's the quiet laying of a foundation strong enough to hold every person who needs it. That work is happening right now, even when it looks like waiting.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The intelligence that created you is still creating.
97%
No psychedelic drug gets full US approval before August 2026
The FDA (the US drug regulator) will not give MDMA or psilocybin full legal drug status by mid-August 2026. Neither substance even has a review deadline scheduled in that window. This means doctors still cannot officially prescribe either drug as an approved medicine.
→ No MDMA or psilocybin drug will be officially approved in the US before August 2026. (97% confidence)
Resolves: 2026-08-16 · USA
REGULATION
the precise call ▾
No full FDA approval of any MDMA or psilocybin product occurs by mid-August 2026.. No MDMA or psilocybin NDA/BLA has an FDA action date within the next 30 days, and any pending resubmission would require a public review timeline. A near-term approval is effectively ruled out. || RESOLUTION RULE: YES if, as of 2026-08-16, the FDA has NOT granted full marketing approval to any MDMA-
90%
MDMA and psilocybin stay in the most restricted drug category through mid-2026
The DEA (the US drug enforcement agency) places drugs into categories called schedules; Schedule I means a drug is considered to have no accepted medical use and high abuse potential. Both MDMA and psilocybin will stay in that most restrictive category through at least September 2026. No official government paperwork to change that is currently in motion.
→ MDMA and psilocybin will remain federally illegal at the highest restriction level through at least September 2026. (90% confidence)
Resolves: 2026-08-16 · USA
REGULATION
the precise call ▾
DEA maintains Schedule I classification for psilocybin and MDMA through Q3 2026.. DEA has issued no proposed rescheduling rule for either substance; final rescheduling would require a published Federal Register action. None is in the pipeline for the near term. || RESOLUTION RULE: YES if, as of 2026-08-16, both psilocybin and MDMA remain listed in Schedule I of the Controlled Sub
85%
Psilocybin and MDMA won't get full US drug approval in all of 2026
Even with a full year on the clock, neither MDMA nor psilocybin will earn complete FDA approval as a medicine in 2026. Companies may make some progress — like resubmitting their applications or navigating special restricted-access programs — but the finish line is still out of reach. Real patients hoping for an approved prescription option will have to wait longer.
→ No psychedelic drug will be fully FDA-approved by December 31, 2026. (85% confidence)
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No full FDA approval of MDMA or psilocybin occurs in 2026; any progress is via REMS-gated pathways or resubmission.. FDA approval requires durable efficacy and functional-unblinding resolution; resubmissions take quarters. No MDMA or psilocybin NDA/BLA is positioned for full approval within 2026's remaining months. || RESOLUTION RULE: YES if, as of 2026-12-31, the FDA has NOT granted full marketing approval (NDA/B
83%
US Congress won't legalize or federally approve psychedelics in 2026
Even though some politicians in both parties are interested in psychedelics, interest doesn't equal votes. No bill that would remove psilocybin or MDMA from the federal banned list is close to passing in 2026. Election-year politics make bold drug reform even less likely to get a floor vote.
→ Congress will not pass any law legalizing or federally approving psychedelics in 2026. (83% confidence)
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
No federal descheduling or standalone psychedelic legalization passes Congress in 2026.. Bipartisan interest translates to hearings and study provisions, not descheduling votes in an election year. No bill removing psilocybin/MDMA from Schedule I is near floor passage. || RESOLUTION RULE: YES if, as of 2026-12-31, no federal legislation descheduling or legalizing psilocybin or MDMA has
72%
Compass Pathways stock likely stays under $20 through September 2026
Compass Pathways (ticker: CMPS) is a company developing psilocybin-based treatments. Its stock price tends to move based on excitement and news, not profits. Without a major win — like an FDA approval or a strong late-stage clinical trial result — there's no obvious reason the stock would break above $20 before the end of September 2026.
→ Compass Pathways stock will most likely stay below $20 through September 30, 2026, unless something big and unexpected happens. (72% confidence)
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
Compass Pathways (CMPS) shares remain below $20 at end of Q3 2026 absent a regulatory de-risking catalyst.. Small-cap psychedelic equities trade on momentum, not fundamentals; without an FDA approval or Phase 3 readout materially de-risking the program, CMPS lacks a driver to rerate above the $20 threshold near-term. || RESOLUTION RULE: YES if the closing price of Compass Pathways (NASDAQ: CMPS) on 2026-0